In this article, we will be taking a look at the 12 Healthcare Stocks with Insider Buying in 2025.
In 2025, there will be a complicated combination of opportunities and difficulties in the healthcare innovation landscape, with divergent trends in technology adoption, investment, and fundraising. About $3 billion was raised in the first half of this year by U.S. healthcare venture capital (VC), which is a significant drop and might be the poorest year for healthcare fundraising in more than ten years. This slowdown is a result of macroeconomic factors that affect funding and operations, including rising interest rates, inflation worries, geopolitical tensions, and policy uncertainties. With significant activity in biopharma mergers, acquisitions, and strategic licensing agreements, the private healthcare markets continue to be robust in spite of these challenges.
One promising development in the industry is artificial intelligence (AI). Since 2022, the volume of healthtech AI deals has almost doubled, making it a major source of capital for innovation. Due to investor interest in AI solutions that enhance clinical decision support, imaging, and operational efficiency, digital health startups raised $6.4 billion in venture capital funding in the first half of 2025, up from $6 billion in the same period in 2024. Furthermore, China now plays a far bigger role in biopharma licensing—it spent $3 billion on transactions in H1 2025 alone, more than it did in 2024—but U.S. biopharma investment is still strong.
But there is a lot of pressure on the larger healthcare industry. On CNBC’s “The Exchange,” Mizuho healthcare strategist Jared Holz emphasized that the industry is experiencing unprecedented strain, with managed care and large-cap pharmaceuticals taking the brunt of the burden. He said that, aside from market downturns, healthcare has not outperformed the market in the last ten years, and that the current state of affairs is the worst the industry has seen in decades.
Strategic acquisitions, early-stage investments, and a possible resurgence in initial public offerings (IPOs) indicate that the industry is still ready for innovation in spite of these obstacles. Despite financial challenges, healthcare is poised for growth and revolution as AI-driven solutions increasingly address long-standing inefficiencies. The industry is at a critical juncture where it must balance technological advancements with economic challenges that could influence its course in the future.
With these trends in mind, we will now take a look at the healthcare stocks with Insider Buying in 2025.
Our Methodology
For our methodology, we began by screening stocks using the Stock Analysis screener, applying filters for a market capitalization above $2 billion and insider ownership greater than 20%. From the filtered results, we identified the companies with the highest insider ownership and ranked them in ascending order.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
Here is our list of the 12 healthcare stocks with Insider Buying in 2025.
12. Mesoblast Limited (NASDAQ:MESO)
Insider Shares: 33.76%
Mesoblast Limited (NASDAQ:MESO) is a global leader in developing allogeneic, off-the-shelf cellular medicines for inflammatory diseases. Using its proprietary mesenchymal lineage cell platform, the company targets severe and life-threatening conditions by modulating immune responses and promoting tissue repair. Its lead product, Ryoncil® (remestemcel-L), recently became the first FDA-approved allogeneic mesenchymal stromal cell therapy for pediatric patients with steroid-refractory acute graft versus host disease (SR-aGvHD). MESO is among the stocks with insider buying.
In late September 2025, Mesoblast Limited (NASDAQ:MESO) reaffirmed that all its cell therapy products, including Ryoncil®, are manufactured from U.S. donors in the United States and officially designated as U.S.-origin products. This designation exempts them from pharmaceutical import tariffs, giving the firm a significant commercial edge while underscoring its commitment to U.S.-based manufacturing and regulatory compliance.
Looking ahead, MESO is advancing the commercial launch of Ryoncil® while also progressing regulatory pathways for other therapies. Its Biologic License Application for Revascor®, aimed at treating ischemic heart failure, is under FDA review. At the same time, the business is expanding the development of rexlemestrocel-L for chronic conditions such as heart failure and low back pain.
11. ImmunityBio, Inc. (NASDAQ:IBRX)
Insider Shares: 43.07%
ImmunityBio, Inc. (NASDAQ:IBRX) is advancing its position as a leader in immunotherapy, focusing on cancer and immune disorders through its flagship therapy ANKTIVA®, which combines IL-15 superagonist N-803 with Bacillus Calmette-Guérin (BCG) for patients with non-muscle invasive bladder cancer (NMIBC) unresponsive to BCG. The company is also expanding ANKTIVA’s use across new indications while progressing trials in lung cancer and lymphopenia.
In 2025, IBRX reported strong commercial momentum. Second-quarter revenue reached $26.4 million, up 60% from Q1, bringing year-to-date sales to $43 million. Since J-code approval streamlined reimbursement, unit sales have surged 246%. A lot of urology practices have joined the company’s Expanded Access Program for recombinant BCG, a move aimed at alleviating supply shortages and improving patient access. Internationally, the UK’s regulatory agency approved ANKTIVA plus BCG for BCG-unresponsive NMIBC carcinoma in situ, further broadening its market reach.
On the regulatory front, ImmunityBio, Inc. (NASDAQ:IBRX) is working closely with the FDA after receiving a Refuse-to-File letter for its supplemental biologics license application (sBLA) seeking expansion to papillary-only NMIBC. Meanwhile, the corporation is pushing for guideline updates through the National Comprehensive Cancer Network (NCCN), which could strengthen ANKTIVA’s adoption in U.S. clinical practice.
IBRX is also making progress in oncology trials. It launched the ResQ201A randomized trial evaluating N-803 with tislelizumab in second-line non-small cell lung cancer patients and is preparing international submissions for broader trial participation. Additionally, the FDA has shown support for the firm’s lymphopenia program, with expanded access now available for patients with solid tumors who failed first-line therapies.
To support these initiatives, ImmunityBio, Inc. (NASDAQ:IBRX) recently raised $80 million in equity financing, ensuring resources for ongoing regulatory discussions, clinical trials, and commercial expansion.
10. OPKO Health, Inc. (NASDAQ:OPK)
Insider Shares: 44.01%
OPKO Health, Inc. (NASDAQ:OPK) is a diversified healthcare company with operations spanning diagnostics, pharmaceuticals, and innovative therapies. Its business is anchored by BioReference Laboratories and a growing pipeline focused on immuno-oncology, immune rejuvenation, and metabolic disorders such as obesity.
In 2025, the company drew attention with notable insider buying. CEO Phillip Frost, OPKO’s largest shareholder with roughly 31% ownership, joined other key investors in boosting stakes, bringing the top five holders’ combined ownership to 51%. Recent share purchases around $1.32 suggest strong insider confidence in the company’s long-term outlook.
On the clinical front, OPK advanced a Phase 1 Epstein-Barr virus (EBV) vaccine in partnership with Merck, testing safety in up to 200 healthy adults. Results could lead to Phase 2 trials as early as next year. Its ModeX division continues to drive innovation in immuno-oncology, with four candidates in the pipeline, including MDX2001, a tetraspecific antibody for solid tumors now in Phase 1 trials. Other programs target lymphoma, leukemia, and immune dysfunction. OPK is also among stocks with insider buying, reflecting confidence from key shareholders in its pipeline and strategic direction.
Beyond oncology, OPKO Health, Inc. (NASDAQ:OPK) is addressing metabolic disorders through a collaboration with Entera Bio on OPK-88006, an oral dual GLP-1/glucagon agonist for obesity. Data presented at ENDO 2025 showed encouraging pharmacologic and pharmacokinetic results, with both oral and injectable formulations in development to meet the growing demand for obesity treatments.
Financially, OPK reported Q2 2025 revenue of $156.8 million, reflecting a decline from the prior year. However, the business recently sold select oncology testing assets from BioReference to Labcorp, a move designed to streamline operations and improve liquidity. With projected 2025 revenues of $640–$660 million, OPK is leaning on its pipeline, cost savings, and strategic divestitures to strengthen margins and move toward profitability.
9. Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)
Insider Shares: 46.26%
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) continues to strengthen its position in generic, branded, and specialty medicines, marking September 2025 with key regulatory milestones and financial progress.
On September 26, AMRX submitted a Biologics License Application (BLA) for a biosimilar to XOLAIR® (omalizumab), targeting a multi-billion-dollar market that includes asthma, chronic rhinosinusitis, food allergies, and chronic urticaria. This marks a significant step in expanding into the U.S. biosimilars market.
Earlier in the month, Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) secured multiple FDA approvals. On September 23, Amneal received clearance for Bimatoprost Ophthalmic Solution 0.01%, a treatment for open-angle glaucoma and ocular hypertension with a reference market of about $685 million annually. On September 4, the FDA approved Risperidone Extended-Release Injectable Suspension, a therapy for schizophrenia and Bipolar I disorder maintenance. This complex injectable, which carries 180-day exclusivity under the Competitive Generic Therapy designation, is expected to launch in Q4 2025. Amneal also gained approval for Sodium Oxybate Oral Solution, further broadening its specialty portfolio.
Financial results have reinforced this momentum. In Q2 2025, the corporation reported revenue of $725 million, up 3% year-over-year, with net income of $22 million and a 13% rise in adjusted EBITDA to $184 million. These results prompted an upgraded full-year outlook, with projected adjusted EBITDA of $665–$685 million and EPS of $0.70–$0.75.
Strategically, Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) completed a $2.7 billion debt refinancing, extending maturities to 2032 and lowering interest costs, bolstering financial flexibility to support its growth trajectory. Together, these regulatory wins and financial moves underline AMRX’s focus on scaling complex generics and specialty medicines while positioning for long-term expansion.
8. Caris Life Sciences, Inc. (NASDAQ:CAI)
Insider Shares: 48.01%
Caris Life Sciences, Inc. (NASDAQ:CAI) is advancing its position as a leader in precision medicine by combining whole exome and transcriptome sequencing with AI-driven insights to support cancer detection, monitoring, and therapy selection.
The company delivered strong second-quarter results for 2025, reporting $181.4 million in revenue, up 81% year-over-year, with molecular profiling revenue climbing nearly 86%. Caris Life Sciences, Inc. (NASDAQ:CAI) completed more than 50,000 clinical therapy selection cases, while gross margins expanded to 62.7% from 37.5% a year ago. Importantly, the business turned profitable on an adjusted EBITDA basis, generating $16.7 million in EBITDA and $5.9 million in free cash flow. These strong fundamentals, combined with recent stocks with insider buying, underscore investor confidence in CAI’s growth trajectory.
Scientifically, CAI continues to strengthen its leadership in precision oncology. Recent findings published in the New England Journal of Medicine validated the company’s work on tumor-infiltrating clonal hematopoiesis (TI-CH), a phenomenon that can confound mutation analysis and treatment decisions. This reinforces CAI’s commitment to refining diagnostic accuracy in oncology.
Recently, Caris Life Sciences, Inc. (NASDAQ:CAI) highlighted the clinical validation of its MI Cancer Seek® assay, an FDA-approved AI-enabled liquid biopsy platform designed for early cancer detection, minimal residual disease monitoring, and therapy guidance. Recent studies demonstrated its broad clinical utility across solid tumors and tissue-agnostic settings, underscoring its potential as a transformative diagnostic tool.
The corporation also published new data on sequencing strategies in breast cancer subgroups, illustrating how its AI-driven molecular insights can directly inform treatment choices. Together, these advances showcase CAI’s focus on applying cutting-edge science and AI to deliver more precise, personalized cancer care.
7. Phibro Animal Health Corporation (NASDAQ:PAHC)
Insider Shares: 50.06%
Phibro Animal Health Corporation (NASDAQ:PAHC) reported strong growth in 2025, driven by expanded product lines and rising global demand. Operating across about 90 countries, the company serves both food and companion animals through its portfolio of medicated feed additives (MFAs), nutritional products, vaccines, and specialty ingredients.
For fiscal Q4 2025, Phibro Animal Health Corporation (NASDAQ:PAHC)’s net sales surged 39% to $378.7 million, fueled by a 53% increase in its Animal Health segment. MFA sales jumped 77%, largely from the successful acquisition and integration of Zoetis’ MFA portfolio and robust demand in Latin America. Specialty nutritional products and vaccines also contributed to gains. Overall, fiscal 2025 net sales rose 27% to $1.29 billion, with significant improvements in net income and adjusted EBITDA.
The Zoetis acquisition, which added more than 37 products and six manufacturing sites worldwide, has been central to Phibro’s recent momentum. The firm is also expanding in the companion animal market and seeing global adoption of OmniGen-AF, a nutritional supplement for the dairy industry.
Investor confidence has followed these results. PAHC’s stock is up more than 80% year-to-date in 2025, outpacing both peers and the broader market. Analysts have raised earnings forecasts for fiscal 2025 and 2026, reflecting optimism around continued growth. Looking ahead, PAHC projects $1.43 to $1.48 billion in revenue and $225–$235 million in adjusted EBITDA for fiscal 2026, underscoring confidence in its trajectory.
6. PACS Group, Inc. (NYSE:PACS)
Insider Shares: 71.76%
PACS Group, Inc. (NYSE:PACS), a leading post-acute care provider, has been in focus this September amid regulatory challenges and operational growth. The Utah-based company operates 316 facilities across 17 states, with more than 32,000 skilled nursing beds and 2,400 assisted living beds, emphasizing quality care. Most facilities hold 4- or 5-star CMS ratings. Since Q2 2024, PACS has expanded rapidly, adding 96 facilities to its portfolio.
In September, the New York Stock Exchange extended PACS’s trading period to November 19, 2025, giving the company more time to complete restatements of financial statements from early and mid-2024 and catch up on SEC filings. PACS Group, Inc. (NYSE:PACS) is also cooperating with an independent Audit Committee investigation into past financial matters. Despite these issues, management signaled strong momentum, projecting record revenue and adjusted EBITDA for the first half of 2025 once filings are complete. As of June 30, the business reported 88.9% occupancy, well above the industry’s 78% average, and cash reserves of $294.2 million, nearly double year-end 2024 levels, making it a company to watch among stocks with insider buying.
Leadership changes also marked the month, with CFO Derick Apt resigning after an internal policy investigation. PACS Group, Inc. (NYSE:PACS) appointed a former CFO as interim and added an interim compliance chief to strengthen governance and regulatory oversight.
5. BGM Group Ltd. (NASDAQ:BGM)
Insider Shares: 72.94%
BGM Group Ltd. (NASDAQ:BGM), a China-based pharmaceutical and chemical company, is rapidly transforming into an AI- and biopharma-focused enterprise. Through subsidiaries, the company develops specialty and generic drugs while expanding into intelligent robotics and healthcare technology.
In 2025, BGM reported a 271% surge in total assets to $207.4 million as of March 31, fueled by acquisitions such as Patriton Limited and HM Management Company Limited. BGM Group Ltd. (NASDAQ:BGM) also acquired Xingdao Intelligent, specializing in AI-powered robotics, and YD Network, focused on AI in stock trading. Despite this expansion, the firm posted a net loss of $0.9 million in the first half of 2025, reflecting the high costs of its transformation.
The corporation is also strengthening its healthcare presence through the acquisition of Wonder Dragon Global, which adds inventories of Qingzhuan dark tea. BGM plans to leverage AI to develop health-focused products, including ginseng and goji berry tea variants with potential medicinal applications. Leadership changes this year saw the CEO assume the chairman role to align governance with BGM’s technology-driven strategy.
In September 2025, institutional investors have shown interest in BGM Group Ltd. (NASDAQ:BGM)’s pivot, and insiders have increased their holdings, signaling confidence in the company’s future. Shares have gained over 35% in the past month, reflecting optimism around its strategic shift, though the stock remains volatile. Looking ahead, the business has allocated $1.4 million for capital expenditures to scale AI and biopharma operations, with a focus on cost efficiency and expanding its multi-agent AI productivity platform.
4. Pulse Biosciences, Inc. (NASDAQ:PLSE)
Insider Shares: 73.42%
Pulse Biosciences, Inc. (NASDAQ:PLSE) is advancing bioelectric medicine through its proprietary Nano-Pulse Stimulation (NPS) technology, targeting immuno-oncology, dermatology, and cardiac ablation. The company’s Nanosecond Pulsed Field Ablation (nsPFA) system offers non-thermal cellular treatment approaches and has gained FDA Breakthrough Device Designation for its potential to transform cardiac therapies.
A key milestone came with FDA approval to initiate a clinical study of the nsPFA Cardiac Surgery System for atrial fibrillation in September 2025, enrolling up to 136 patients across 20 sites, including international locations. This positions PLSE at the forefront of innovative cardiac treatments and highlights why it is closely monitored among stocks with insider buying.
In September 2025, Pulse Biosciences, Inc. (NASDAQ:PLSE) reported its first successful procedures in the PRECISE-BTN study, evaluating its nsPFA Percutaneous Electrode System for benign thyroid nodules (BTNs). The multicenter trial involves 50 patients across four sites, focusing on safety, nodule volume reduction, symptom relief, and quality of life. Early results are promising, showing significant reductions in nodule size.
3. SS Innovations International, Inc. (NASDAQ:SSII)
Insider Shares: 75.93%
SS Innovations International, Inc. (NASDAQ:SSII) is advancing affordable surgical robotics with its flagship SSi Mantra system, offering a cost-efficient alternative to established platforms like Intuitive Surgical’s da Vinci. Approved in seven countries, including India, Indonesia, and the Philippines, the company is pursuing regulatory approval in the U.S. and Europe to expand its global footprint.
In September 2025, Naveen Kumar Amar was appointed Chief Financial Officer, bringing extensive international finance experience as SSII ramps up sales and prepares submissions for a U.S. FDA 510(k) application by October and CE mark certification in Europe in the first half of 2026.
Financially, SS Innovations International, Inc. (NASDAQ:SSII) posted strong growth in Q2 2025, with revenue rising 121.8% to $10 million and gross profit more than tripling year-over-year. Installations of the SSi Mantra system surged 130% year-over-year, bringing the total installed base to 105 systems performing 4,657 surgeries as of June 30, 2025. Among its achievements, the firm performed the world’s first intercontinental robotic cardiac telesurgery in July 2025, highlighting its technological capabilities.
2. Summit Therapeutics Inc. (NASDAQ:SMMT)
Insider Shares: 80.15%
Summit Therapeutics Inc. (NASDAQ:SMMT) is a biopharmaceutical company focused on oncology, developing therapies for non-small cell lung cancer (NSCLC) and other unmet medical needs. Its lead investigational drug, ivonescimab, targets EGFR-mutated NSCLC patients, particularly those who have progressed after third-generation EGFR tyrosine kinase inhibitors (TKIs).
In September 2025, SMMT provided updates on ivonescimab’s Phase III HARMONi trial during the World Conference on Lung Cancer (WCLC 2025). The trial evaluates ivonescimab combined with platinum-doublet chemotherapy versus chemotherapy plus placebo in advanced or metastatic non-squamous NSCLC patients with EGFR mutations. Top-line results released in May 2025 showed a statistically significant improvement in progression-free survival, with positive trends in overall survival, although not statistically significant.
Ivonescimab is already approved for first-line treatment in China for PD-L1-positive advanced NSCLC, marking a key commercial milestone. Summit Therapeutics Inc. (NASDAQ:SMMT) continues to expand clinical programs with ongoing HARMONi-3 and HARMONi-7 Phase III trials, including enrollment in the U.S., signaling a strategic push for broader regulatory approvals and global market adoption.
1. Regencell Bioscience Holdings Limited (NASDAQ:RGC)
Insider Shares: 88.56%
Regencell Bioscience Holdings Limited (NASDAQ:RGC) tops our list for being one of the stocks with insider buying. It is a Hong Kong-based biopharmaceutical company developing Traditional Chinese Medicine (TCM) treatments for neurocognitive disorders such as ADHD and autism spectrum disorder (ASD).
A key milestone came on September 21, 2025, when RGC was added to the S&P Global BMI Index, boosting its visibility among institutional and passive investors. This inclusion may enhance liquidity and help stabilize the stock, which has been highly volatile. Despite this progress, the business continues to face fundamental challenges, including zero revenue, ongoing losses, and uncertain regulatory pathways for its treatments.
On the clinical front, Regencell Bioscience Holdings Limited (NASDAQ:RGC) reported positive results from its second efficacy trial using standardized TCM formulae for ADHD and ASD, showing a mean symptom improvement of 37% with no adverse side effects. While encouraging, no FDA-approved products have been announced yet, and the treatments remain investigational.
Regencell Bioscience Holdings Limited (NASDAQ:RGC)’s stock experienced extreme volatility in mid-2025, peaking with an approximate 14,899% year-to-date gain by June, driven by speculative trading, a stock split, and excitement over trial results. Following this peak, shares saw sharp intra-day swings and a pullback, though technical indicators in September suggest a potential upward trend, supported by positive momentum and movement above its 50-day moving average.
While we acknowledge the potential of RGC to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than RGC and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
